# EMPOWER-Lung 1 (NCT03088540)

> Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03088540
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Regeneron Pharmaceuticals
- Conditions: Carcinoma，Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer
- Interventions: Pemetrexed; Paclitaxel; Gemcitabine; Cisplatin; Carboplatin; cemiplimab
- Enrollment: 712
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-free Survival (PFS) Per Blinded IRC

## Indexed commentary on EMPOWER-Lung 1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 38
- YouTube: 18
- Podcasts: 16

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=empower-lung-1-nct03088540

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03088540", "email": "<work email>"}; the inbox owner confirms by the emailed link.